Search results for "Tapentadol"

showing 6 items of 6 documents

Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.

2014

Abstract Abstract Objective: The aim of this study was to assess the efficacy and tolerability of tapentadol (TP) for a period of 4 weeks in patients who were already treated by opioids. Methods: A convenience sample of 30 patients was selected for a prospective observational cohort study. Cancer patients who were receiving at least 60 mg of oral morphine equivalents were selected. Patients discontinued their previous opioid analgesics before starting TP, in doses calculated according the previous opioid consumption (1:3.3 ratio with oral morphine equivalents). The subsequent doses were changed according to the patients' needs for a period of 4 weeks. Oral morphine was offered as a breakthr…

MalePalliative careReceptors Opioid muAdverse effectSettore MED/42 - Igiene Generale E ApplicataCohort StudiesNeoplasmsReceptorsDrug Dosage CalculationsProspective StudiesAdverse effects; Cancer pain; Palliative care; TapentadolCancer painPain MeasurementAnalgesicsMorphineMedicine (all)General MedicineMiddle AgedTapentadolAnalgesics OpioidTapentadolTreatment OutcomeItalyTolerabilityAnesthesiaPalliative careFemaleDrugDrug Monitoringmedicine.drugCohort studyAdverse effects; Cancer pain; Palliative care; Tapentadol; Aged; Analgesics Opioid; Cohort Studies; Dose-Response Relationship Drug; Drug Dosage Calculations; Drug Monitoring; Female; Humans; Italy; Karnofsky Performance Status; Male; Middle Aged; Morphine; Neoplasms; Pain Management; Pain Measurement; Phenols; Prospective Studies; Receptors Opioid mu; Treatment Outcome; Pain; Medicine (all)PainOpioidDose-Response RelationshipPhenolsmedicineHumansPain ManagementKarnofsky Performance StatusAdverse effectAgedDose-Response Relationship DrugAdverse effectsbusiness.industryCancermedicine.diseaseOpioidmubusinessCancer pain
researchProduct

Tapentadol in cancer pain management: a prospective open-label study.

2012

OBJECTIVES: The aim of this prospective, open-label study was to evaluate the efficacy and tolerability of tapentadol (TP) in the management of cancer pain. METHODS: A 4 weeks' prospective study was carried out in 50 opioid-naive cancer patients with moderate-severe pain. Each patient initially received twice-daily doses of slow-release TP 50 mg. Doses were then managed to maintain adequate relief or dose-limiting toxicity, on the basis of the clinical response. The following parameters were recorded at weekly intervals for 4 weeks: pain and opioid-related adverse effects, quality of life measured with the Spitzer score, TP escalation index percent (TPEI%) and TP escalation index in mg (TPE…

MaleSettore MED/41 - AnestesiologiaPainNeuropathic painCancer pain Neuropathic pain Opioids Tapentadol AnalgesiaQuality of lifePhenolsNeoplasmsMedicineCancer pain; Neuropathic pain; Opioids; Tapentadol; Aged; Analgesics; Female; Humans; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Phenols; Prospective Studies; Medicine (all)HumansProspective StudiesCancer painAdverse effectProspective cohort studyAgedPain MeasurementAnalgesicsbusiness.industryMedicine (all)General MedicineMiddle AgedTapentadolClinical trialOpioidsTapentadolTolerabilityAnesthesiaNeuropathic painFemaleCancer painbusinessmedicine.drugCurrent medical research and opinion
researchProduct

Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids

2013

Objectives: The aim of this exploratory study was to assess the conversion ratios between tapentadol and other opioids in patients requiring an opioid switching. Methods: A prospective study was carried out in a convenience sample of consecutive patients admitted to an acute palliative care unit and a home care unit for a period of 1 year. Patients who were switched from/to tapentadol were selected. The initial ratio between tapentadol and other opioids, expressed as oral morphine equivalents was 1:3.3. The subsequent doses were flexible and were changed to fit the patients’ needs. Pain intensity and distress score were recorded until opioid doses were stable. In all, 37 patients were exami…

NarcoticsPalliative careReceptors Opioid muPainSettore MED/41 - AnestesiologiaOpioidPhenolsNeoplasmsReceptorsmedicineHumansIn patientProspective StudiesCancer painProspective cohort studyConversion ratioAnalgesicsMorphinebusiness.industryMedicine (all)Palliative CareCancerGeneral MedicineTapentadolmedicine.diseaseAnalgesics OpioidTapentadolOpioidmuDelayed-Action PreparationsAnesthesiaCancer pain; Conversion ratio; Opioid switching; Tapentadol; Analgesics Opioid; Delayed-Action Preparations; Humans; Morphine; Narcotics; Neoplasms; Pain; Palliative Care; Phenols; Prospective Studies; Receptors Opioid mu; Medicine (all)Opioid switchingExtended releasebusinessCancer painCancer pain Conversion ratio Opioid switching Tapentadol Analgesiamedicine.drugCurrent Medical Research and Opinion
researchProduct

Spinal neuronal correlates of tapentadol analgesia in cancer pain: A back-translational approach

2014

Background Pain is a common and highly debilitating complication for cancer patients significantly compromising their quality of life. Cancer-induced bone pain involves a complex interplay of multiple mechanisms including both inflammatory and neuropathic processes and also some unique changes. Strong opioids are a mainstay of treatments but side effects are problematic and can compromise optimal pain control. Tapentadol is a novel dual-action drug, both stimulating inhibitory μ-opioid receptors (MOR) and mediating noradrenaline reuptake inhibition (NRI) leading to activation of the inhibitory α-2 adrenoceptor. It has been demonstrated to treat effectively both acute and chronic pain. We he…

business.industryChronic painAtipamezole(+)-NaloxonePharmacologyTapentadolmedicine.disease3. Good healthAnesthesiology and Pain MedicineOpioidMedicinePremovement neuronal activitymedicine.symptombusinessBone painCancer painmedicine.drugEuropean Journal of Pain
researchProduct

Palexia crystals in gastrointestinal tract, a new entity associated with death following gastrointestinal hemorrhage

2015

medicine.medical_specialtyGastrointestinal tractbusiness.industryInternal medicineAnesthesiamedicineCell BiologyGeneral MedicineToxicologybusinessTapentadol HydrochlorideGastroenterologyPathology and Forensic MedicineExperimental and Toxicologic Pathology
researchProduct

The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review

2017

The aim of this review was to assess the role of tapentadol given at medium-high doses in opioid-tolerant patients for cancer pain management in place of step-3 analgesics.A systematic literature search was performed out of which six studies and one secondary analysis provided data regarding tapentadol used as a step-3 analgesic for this review. Tapentadol, when used at ≥60 mg of oral morphine equivalents in opioid-tolerant patients with cancer pain, or passing from step-2 doses to ≥60 mg of oral morphine equivalents, was well tolerated and effective and could be considered as a flexible drug to be used for the management of moderate-to-severe cancer pain. The limited occurrence of gastroin…

medicine.medical_specialtyPalliative careVomitingNauseaAnalgesicContext (language use)03 medical and health sciences0302 clinical medicinePhenolsNeoplasmsHumansMedicine030212 general & internal medicineAdverse effectIntensive care medicinePain MeasurementMorphinebusiness.industryNauseaCancer PainGeneral MedicineTapentadolAnalgesics OpioidTapentadolOpioidAnesthesiamedicine.symptombusinessCancer painConstipation030217 neurology & neurosurgerymedicine.drugCurrent Medical Research and Opinion
researchProduct